• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

中空纤维系统模型在结核病中的应用：欧洲药品管理局的经验。

Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.

机构信息

Human Medicines Evaluation Division-Anti-infectives and Vaccines.

Human Medicines Research and Development Support Division-Scientific Advice, European Medicines Agency, London, United Kingdom.

出版信息

Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S1-4. doi: 10.1093/cid/civ484.

DOI:10.1093/cid/civ484
PMID:26224766
Abstract

The in vitro hollow fiber system model has been qualified by the European Medicines Agency as a methodology for use in support of selection and development of antituberculosis regimens. More data are expected to be generated in the future to further characterize its value.

摘要

体外中空纤维系统模型已被欧洲药品管理局确认为一种支持抗结核方案选择和开发的方法学。预计未来将产生更多数据，以进一步确定其价值。

相似文献

1
Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.中空纤维系统模型在结核病中的应用：欧洲药品管理局的经验。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S1-4. doi: 10.1093/cid/civ484.
2
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.系统分析结核病实验中空纤维模型。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S10-7. doi: 10.1093/cid/civ425.
3
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.中空纤维结核系统作为一种新型药物研发工具的战略监管评估和认可。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S5-9. doi: 10.1093/cid/civ424.
4
Drug Sensitivity Testing of Mycobacterium tuberculosis Growing in a Hollow Fiber Bioreactor.中空纤维生物反应器中生长的结核分枝杆菌的药敏试验。
Methods Mol Biol. 2021;2314:715-731. doi: 10.1007/978-1-0716-1460-0_31.
5
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.结核中空纤维模型与结核患者治疗事件的相关性：学习与确认。
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S18-24. doi: 10.1093/cid/civ426.
6
The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.抗结核药物治疗方案非临床评价中的中空纤维系统模型
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S32-3. doi: 10.1093/cid/civ460.
7
Preclinical Efficacy Testing of New Drug Candidates.新药候选物的临床前疗效测试。
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017.
8
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.抗结核药物的药代动力学-药效学及剂量反应关系：行业与学术界的建议和标准
J Infect Dis. 2015 Jun 15;211 Suppl 3:S96-S106. doi: 10.1093/infdis/jiu610.
9
Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.二线抗结核药物给药的药代动力学/药效学背景和方法以及科学证据基础。
Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. doi: 10.1093/cid/ciy608.
10
Current challenges in drug discovery for tuberculosis.结核病药物研发中的当前挑战。
Expert Opin Drug Discov. 2017 Jan;12(1):1-4. doi: 10.1080/17460441.2017.1255604. Epub 2016 Nov 11.

引用本文的文献

1
Identification of oncology pharmacokinetic drivers through in vitro experiments and computational modeling.通过体外实验和计算建模确定肿瘤学药代动力学驱动因素。
J Pharmacokinet Pharmacodyn. 2025 Jul 23;52(4):40. doi: 10.1007/s10928-025-09986-3.
2
Dynamic PK/PD Infection Models for the Development and Optimisation of Antimicrobial Regimens: A Narrative Review.用于抗菌治疗方案开发与优化的动态药代动力学/药效学感染模型：叙述性综述
Antibiotics (Basel). 2024 Dec 10;13(12):1201. doi: 10.3390/antibiotics13121201.
3
Application of the Hollow-Fiber Infection Model to Personalized Precision Dosing of Isoniazid in a Clinical Setting.
中空纤维感染模型在临床个体化异烟肼精准给药中的应用。
J Korean Med Sci. 2024 Apr 8;39(13):e104. doi: 10.3346/jkms.2024.39.e104.
4
Research in the Field of Drug Design and Development.药物设计与开发领域的研究
Pharmaceuticals (Basel). 2023 Sep 11;16(9):1283. doi: 10.3390/ph16091283.
5
antimicrobials inherited and the non-inherited resistance: mechanisms and alternative therapeutic strategies.抗菌药物的固有耐药性和非固有耐药性：机制及替代治疗策略
Front Microbiol. 2023 May 25;14:1176317. doi: 10.3389/fmicb.2023.1176317. eCollection 2023.
6
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments.应用蒙特卡罗实验确定德拉马尼的药代动力学/药效学敏感性折点。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0140122. doi: 10.1128/aac.01401-22. Epub 2023 Mar 6.
7
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development.中空纤维系统模型可重现结核病，并且对药物和联合疗法开发的最佳实践制定了性能规格。
J Antimicrob Chemother. 2023 Apr 3;78(4):953-964. doi: 10.1093/jac/dkad029.
8
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of , methodologies and human studies.抗结核药物的药代动力学和药效学：方法学与人体研究评估
Front Pharmacol. 2022 Dec 9;13:1063453. doi: 10.3389/fphar.2022.1063453. eCollection 2022.
9
Advances in the design of combination therapies for the treatment of tuberculosis.结核病治疗联合疗法设计的新进展。
Expert Opin Drug Discov. 2023 Jan;18(1):83-97. doi: 10.1080/17460441.2023.2157811. Epub 2022 Dec 28.
10
The Application of Hollow Fiber Cartridge in Biomedicine.中空纤维柱在生物医学中的应用。
Pharmaceutics. 2022 Jul 18;14(7):1485. doi: 10.3390/pharmaceutics14071485.